Previous 10 | Next 10 |
Cost of Sales: In the first three months of 2021, cost of sales increased to € 5.0 million (3M 2020: € 3.3 million). Research and Development (R&D) Expenses: In the first three months of 2021, research and development expenses were € 33.3 million (3M 2020: €...
Conference Call Alert Invitation to MorphoSys' First Quarter Results Conference Call on May 6, 2021 MUNICH, GERMANY / ACCESSWIRE / April 28, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ: MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technolo...
Incyte (INCY) and MorphoSys AG (MOR) announce that the first patient has been dosed in a late-stage testing tafasitamab combo in patients with a form of lymphoma.The placebo-controlled Phase 3 inMIND study evaluates the efficacy and safety of tafasitamab or placebo in combination with le...
Incyte (Nasdaq:INCY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announced the first patient has been dosed in the placebo-controlled Phase 3 inMIND study evaluating the efficacy and safety of tafasitamab or placebo in combination with le...
Image source: The Motley Fool. MorphoSys AG (NASDAQ: MOR) Q4 2020 Earnings Call Mar 16, 2021 , 9:00 a.m. ET Operator Continue reading For further details see: MorphoSys AG (MOR) Q4 2020 Earnings Call Transcript
The following slide deck was published by MorphoSys AG in conjunction with their 2020 Q4 earnings call. For further details see: MorphoSys AG 2020 Q4 - Results - Earnings Call Presentation
MorphoSys AG (MOR) Q4 2020 Earnings Conference Call March 16, 2021 9:00 a.m. ET Company Participants Julia Neugebauer - Director, IR Jean-Paul Kress - CEO Roland Wandeler - COO Malte Peters - Chief R&D Officer Sung Lee - CFO Conference Call Participants Geoffrey Porges - SVB Leerink James...
MorphoSys (MOR): Q4 GAAP EPS of -€0.50.Revenue of €36M (+224.3% Y/Y)Press Release For further details see: MorphoSys reports Q$ results
* Percentage point ** Tremfya and Monjuvi are still considered as clinical programs due to ongoing studies in various indications and/or treatment lines *** Including otilimab (MOR103/GSK3196165), which is fully out-licensed to GSK MorphoSys will hold its conference call and webcast tomorrow...
SOURCE: MorphoSys AG View source version on accesswire.com: https://www.accesswire.com/634512/Invitation-to-MorphoSys-Full-Year-Results-2020-Conference-Call-on-March-16-2021
News, Short Squeeze, Breakout and More Instantly...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares (“ADSs”) from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Ex...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG ...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany ...